Document Detail


Treatment of myelodysplastic syndromes with recombinant human erythropoietin.
MedLine Citation:
PMID:  1761122     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
12 patients with myelodysplastic syndromes were treated with recombinant human erythropoietin (r-epo). 5 patients had stable anemia, 78-92 g/l, and 7 were transfusion-dependent. In 11 patients, r-epo was given intravenously three times a week, with dose escalation after 4 and 8 wk if hemoglobin did not increase more than 15 g/l. The doses were 600, 1500 and 3000 U/kg bodyweight/wk. The 12th patient was treated subcutaneously with a dose of 560 U/kg/wk. 3 patients showed a significant response with an increase in hemoglobin of greater than or equal to 15 g/l. 2 of these had stable anemia before treatment and increased in hemoglobin from 87 to 116 g/l and from 80 to 99 g/l, respectively. The 3rd patient was transfusion-dependent and rose to a stable hemoglobin level between 76 and 80 g/l without transfusions. 2 patients showed a reduction of their transfusion need. Mean initial serum erythropoietin in the responding group was 366 U/l compared to 1049 among the non-responders (p = 0.367). Response was observed in 5/7 patients without bone marrow sideroblasts and in 0/5 patients with sideroblasts (p = 0.027). Erythropoietin seems to be an effective and well-tolerated treatment for a certain proportion of patients with MDS. A larger patient material might provide a model for predicting responses.
Authors:
E Hellström; G Birgegård; D Lockner; C Helmers; A Ost; L Wide
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  47     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  1991 Nov 
Date Detail:
Created Date:  1992-02-10     Completed Date:  1992-02-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  355-60     Citation Subset:  IM    
Affiliation:
Department of Medicine, Huddinge Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Drug Administration Schedule
Erythropoietin / therapeutic use*
Female
Fever / etiology
Humans
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Recombinant Proteins / therapeutic use
Thrombocytopenia / etiology
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow ...
Next Document:  Diagnostic utility of the pre-incubated acidified glycerol lysis test in haemolytic and non-haemolyt...